Examining HIV pre-exposure prophylaxis (PrEP) acceptability among rural people who inject drugs: predictors of PrEP interest among syringe service program clients.

Hilary L Surratt, Sarah Brown, Abby L Burton, Will Cranford, Christie Green, Stephanie M Mersch, Rebecca Rains, Philip M Westgate
Author Information
  1. Hilary L Surratt: University of Kentucky, Department of Behavioral Science, College of Medicine, Lexington, Kentucky, USA.
  2. Sarah Brown: Appalachian Regional Healthcare, Barbourville, Kentucky, USA.
  3. Abby L Burton: University of Kentucky, Department of Behavioral Science, College of Medicine, Lexington, Kentucky, USA.
  4. Will Cranford: University of Kentucky, Department of Biostatistics, College of Public Health, Lexington, Kentucky, USA.
  5. Christie Green: Cumberland Valley District Health Department, Manchester, Kentucky, USA.
  6. Stephanie M Mersch: University of Kentucky, Department of Behavioral Science, College of Medicine, Lexington, Kentucky, USA.
  7. Rebecca Rains: Knox County Health Department, Barbourville, Kentucky, USA.
  8. Philip M Westgate: University of Kentucky, Department of Biostatistics, College of Public Health, Lexington, Kentucky, USA.

Abstract

Rural communities in the US have increasing HIV burden tied to injection drug use, yet engagement in pre-exposure prophylaxis (PrEP) care has been low among people who inject drugs (PWID). Syringe service programs (SSPs) are widely implemented in Kentucky's Appalachian region, presenting an important opportunity to scale PrEP services. This paper examines PrEP awareness, interest and preferences among PWID attending community-based SSPs in Appalachia. Eighty participants were enrolled from two SSP locations. Eligibility included:���������18 years old, current injection drug use and SSP use, and an indication for PrEP as defined by CDC guidelines. Participants completed a structured baseline interview. Predictors of PrEP awareness, interest and formulation preferences were examined. 38.8% reported baseline awareness of PrEP, 50% expressed high interest in PrEP, and 48.1%reported a preference for injectable PrEP. Significant bivariate predictors of PrEP interest included: current worry about health, higher perceived HIV risk, higher community HIV stigma, and higher enacted substance use stigma in the past year; in the adjusted model, enacted substance use stigma remained significant. Findings demonstrate substantial interest in PrEP among rural PWID. Intrapersonal and social determinant factors were associated with PrEP interest, which suggests the importance of multi-level intervention targets to increase PrEP uptake.

Keywords

References

  1. J Biomed Inform. 2009 Apr;42(2):377-81 [PMID: 18929686]
  2. AIDS Behav. 2012 May;16(4):1075-83 [PMID: 21785873]
  3. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26 [PMID: 15230939]
  4. J Acquir Immune Defic Syndr. 2017 May 1;75(1):35-44 [PMID: 28225437]
  5. AIDS Educ Prev. 2017 Aug;29(4):315-329 [PMID: 28825858]
  6. Front Public Health. 2021 Dec 07;9:677716 [PMID: 34950622]
  7. AIDS Behav. 2020 Jun;24(6):1942-1950 [PMID: 31853771]
  8. J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e61-e70 [PMID: 33148998]
  9. J Subst Abuse Treat. 2020 Oct;117:108058 [PMID: 32811633]
  10. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):323-331 [PMID: 27763996]
  11. Sex Transm Dis. 2019 Aug;46(8):507-512 [PMID: 31295217]
  12. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):72-77 [PMID: 28902704]
  13. AIDS Care. 2007 Jul;19(6):757-63 [PMID: 17573595]
  14. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):46-53 [PMID: 29847480]
  15. BMC Public Health. 2020 Feb 18;20(1):248 [PMID: 32070318]
  16. Curr HIV/AIDS Rep. 2018 Jun;15(3):245-254 [PMID: 29796965]
  17. Harm Reduct J. 2021 Jun 30;18(1):68 [PMID: 34193165]
  18. Am J Public Health. 2020 Jan;110(1):34-36 [PMID: 31800272]
  19. AIDS Behav. 2021 May;25(5):1490-1506 [PMID: 32749627]
  20. Ann Epidemiol. 2018 Dec;28(12):841-849 [PMID: 29983236]
  21. JAMA Netw Open. 2022 Jul 1;5(7):e2221352 [PMID: 35819788]
  22. Patient Prefer Adherence. 2018 May 24;12:919-927 [PMID: 29872277]
  23. Drug Alcohol Depend. 2016 May 1;162:34-43 [PMID: 26972790]
  24. AIDS Care. 2021 Jun;33(6):721-728 [PMID: 32951438]
  25. Harm Reduct J. 2018 Nov 12;15(1):55 [PMID: 30419926]
  26. Am J Prev Med. 2021 Nov;61(5 Suppl 1):S118-S129 [PMID: 34686281]
  27. Am J Public Health. 2020 Jan;110(1):22-24 [PMID: 31725312]
  28. AIDS Patient Care STDS. 2018 Dec;32(12):529-537 [PMID: 30311777]
  29. BMC Infect Dis. 2022 Sep 14;22(1):737 [PMID: 36104676]
  30. Clin Infect Dis. 2021 May 4;72(9):1615-1622 [PMID: 32211757]
  31. JAMA Netw Open. 2022 Jul 1;5(7):e2221346 [PMID: 35819784]
  32. J Int AIDS Soc. 2019 May;22(5):e25286 [PMID: 31111684]
  33. Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269 [PMID: 31177363]
  34. Health Qual Life Outcomes. 2017 May 30;15(1):115 [PMID: 28558805]
  35. PLoS One. 2020 Apr 16;15(4):e0231424 [PMID: 32298320]
  36. AIDS Behav. 2023 Aug;27(8):2606-2616 [PMID: 36670210]
  37. Am J Public Health. 2019 Sep;109(9):1216-1223 [PMID: 31318587]
  38. Am J Public Health. 1998 Sep;88(9):1403-4 [PMID: 9736888]
  39. Drug Alcohol Depend. 2021 Sep 1;226:108878 [PMID: 34214880]
  40. Ann Epidemiol. 2021 Dec;64:102-110 [PMID: 34563567]
  41. AIDS Behav. 2017 Sep;21(9):2561-2578 [PMID: 27752870]
  42. JAMA. 2023 Jan 3;329(1):63-84 [PMID: 36454551]
  43. J Gen Intern Med. 2023 Mar;38(4):913-921 [PMID: 35614171]
  44. Lancet Reg Health Am. 2023 Jan 17;18:100416 [PMID: 36844011]
  45. J Urban Health. 2008 May;85(3):309-22 [PMID: 18340537]
  46. J Biomed Inform. 2019 Jul;95:103208 [PMID: 31078660]
  47. BMJ Open. 2021 Jul 16;11(7):e047340 [PMID: 34272219]
  48. BMC Infect Dis. 2020 Sep 24;20(1):702 [PMID: 32972393]
  49. Am J Public Health. 2005 Aug;95(8):1439-44 [PMID: 15985649]
  50. J Med Internet Res. 2020 Oct 23;22(10):e23173 [PMID: 33095177]
  51. AIDS Behav. 2020 Sep;24(9):2637-2649 [PMID: 32157490]
  52. Drug Alcohol Depend. 2019 Feb 1;195:148-155 [PMID: 30639794]
  53. J Acquir Immune Defic Syndr. 2015 May 1;69 Suppl 1:S80-91 [PMID: 25867783]
  54. Front Psychiatry. 2022 May 30;13:905314 [PMID: 35706473]
  55. AIDS Behav. 2022 Apr;26(4):1308-1320 [PMID: 34626265]
  56. J Rural Health. 2022 Jun;38(3):620-629 [PMID: 34541715]

Grants

  1. R34 DA053140/NIDA NIH HHS
  2. UL1 TR001998/NCATS NIH HHS

MeSH Term

Humans
Pre-Exposure Prophylaxis
Male
HIV Infections
Female
Substance Abuse, Intravenous
Adult
Rural Population
Needle-Exchange Programs
Patient Acceptance of Health Care
Kentucky
Middle Aged
Health Knowledge, Attitudes, Practice
Anti-HIV Agents
Appalachian Region
Social Stigma
Young Adult

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0PrEPinterestHIVuseamonginjectionpre-exposureprophylaxisPWIDawarenesshigherstigmaruraldrugpeopleinjectserviceSSPspreferencesSSPcurrentbaselinepredictorsenactedsubstanceRuralcommunitiesUSincreasingburdentiedyetengagementcarelowdrugsSyringeprogramswidelyimplementedKentucky'sAppalachianregionpresentingimportantopportunityscaleservicespaperexaminesattendingcommunity-basedAppalachiaEightyparticipantsenrolledtwolocationsEligibilityincluded:���������18yearsoldindicationdefinedCDCguidelinesParticipantscompletedstructuredinterviewPredictorsformulationexamined388%reported50%expressedhigh481%reportedpreferenceinjectableSignificantbivariateincluded:worryhealthperceivedriskcommunitypastyearadjustedmodelremainedsignificantFindingsdemonstratesubstantialIntrapersonalsocialdeterminantfactorsassociatedsuggestsimportancemulti-levelinterventiontargetsincreaseuptakeExaminingacceptabilitydrugs:syringeprogramclientsDrugmethamphetamine

Similar Articles

Cited By (1)